One study found SPARCL-1 was differentially expressed by proteomic analysis in cerebrospinal fluid and was higher in secondary progressive MS versus relapsing–remitting MS but could not replicate this finding in other datasets [29]. Here, SPARCL1 is linked to myeloid sarcoma.